SynthesisJournal of translational medicine2026
Comparative efficacy, immune response, and safety of mRNA versus dendritic cell vaccines in solid tumors: a systematic review and meta-analysis.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundmRNA and dendritic cell vaccines are emerging immunotherapies for solid tumors. However, their relative immunogenicity and clinical efficacy have not been directly compared. We aimed to evaluate the comparative immune response, tumor response, safety, and survival outcomes of mRNA versus dendritic cell vaccines in patients with solid tumors.
methodsWe performed a systematic review and network meta-analysis of clinical trials assessing mRNA and dendritic cell cancer vaccines in patients with solid tumors. We included 60 unique studies (67 trials) with a total of 1777 patients. Outcomes evaluated included immunogenicity (immune response), tumor response (objective response rate and disease control rate), safety (incidence of mild and severe adverse events), and survival (overall and progression-free survival). The review was prospectively registered in PROSPERO (No. CRD420251012772; registered 17 March, 2025).
resultsmRNA vaccines elicited significantly stronger immune responses than dendritic cell vaccines. mRNA vaccine recipients also experienced a higher incidence of adverse events, including mild and severe events. By contrast, dendritic cell vaccines achieved significantly higher objective response and disease control rates. No significant differences in overall survival or progression-free survival were observed between the two vaccine groups. Despite moderate between-trial heterogeneity, the findings were consistent and robust across analyses.
conclusionsThis comprehensive network meta-analysis provides the first comparative evaluation of mRNA versus dendritic cell vaccines in solid tumors. It indicates that while mRNA vaccines induce more potent immunogenicity, dendritic cell vaccines confer better tumor control, with no observed differences in survival outcomes. These findings fill a critical evidence gap and provide an exploratory synthesis highlighting potential strengths and limitations of each vaccine type. Given that most included studies were early-phase, small-sample trials, these findings should be considered hypothesis-generating and interpreted with caution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.